Potential associations of selected polymorphic genetic variants with COVID-19 disease susceptibility and severity
PLoS ONE,
Год журнала:
2025,
Номер
20(1), С. e0316396 - e0316396
Опубликована: Янв. 3, 2025
In
this
study,
we
analyzed
the
potential
associations
of
selected
laboratory
and
anamnestic
parameters,
as
well
12
genetic
polymorphisms
(SNPs),
with
clinical
COVID-19
occurrence
severity
in
869
hospitalized
patients.
The
SNPs
by
qPCR
were
based
on
population-wide
(GWAS)
data
previously
indicating
association
COVID-19,
additional
that
have
been
shown
to
be
important
cellular
processes
also
examined.
We
confirmed
pre-existing
diabetes
found
an
unexpected
between
less
severe
disease
loss
smell
taste.
Regarding
polymorphisms,
a
higher
allele
frequency
LZTFL1
IFNAR2
minor
variants
significantly
correlated
greater
susceptibility
(hospitalization)
severity,
similar
tendency
was
observed
for
RAVER1
MUC5B
variants.
Interestingly,
ATP2B4
haplotype,
protecting
against
malaria,
increased
susceptibility,
while
diabetic
patients
lower
presence
reduced-function
ABCG2
transporter
variant.
Our
current
results,
which
should
reinforced
larger
studies,
indicate
together
may
predictive
value
COVID-19.
Язык: Английский
Short- and long-term comparative effectiveness of nirmatrelvir/ritonavir and molnupiravir in asthma patients: a cohort study
Respiratory Research,
Год журнала:
2025,
Номер
26(1)
Опубликована: Фев. 28, 2025
Abstract
Background
Few
studies
evaluated
the
effectiveness
of
COVID-19
antivirals
specifically
in
asthma
population
This
study
assessed
short-
and
long-term
effects
nirmatrelvir/ritonavir
versus
molnupiravir
population.
Methods
is
a
retrospective
cohort
on
adult
patients
infected
with
COVID-19,
using
real-world
data
obtained
from
health
officials
Hong
Kong.
Key
inclusion
criteria
were
infection
between
March
16,
2022,
Oct
30,
2023,
age
≥
18
years,
previous
diagnosis,
prescription
history
an
medication.
Outcomes
included
acute
post-acute
mortality,
all-cause
hospitalization,
cause-specific
hospitalization.
Results
1,745
eligible
for
this
study,
median
follow-up
time
365
days
(IQR:
335–365).
Patients
group
had
significantly
lower
risks
inpatient
death
(HR,
0·27
[95%
CI,
0·12
to
0·59];
p
=
0·0011),
0·49
0·28
0·85];
0·011),
hospitalization
0·72
0·58
0·89];
0·0020),
myocardial
infarction
0·10
0·01
0·92];
0·042)
than
control
group.
The
risk
was
compared
0·65
0·52
0·81];
0·00012).
Among
who
prescribed
medium-/
high-dose
inhaled
corticosteroids,
hazard
exacerbation
0·35
0·95];
0.030).
Conclusion
Compared
molnupiravir,
may
offer
more
benefits
reducing
sequelae
among
patients.
In
addition,
also
demonstrated
mild
asthma,
which
have
not
been
generally
recommended
existing
clinical
management
guidelines.
Язык: Английский
Genetic Predictors of Paxlovid Treatment Response: The Role of IFNAR2, OAS1, OAS3, and ACE2 in COVID-19 Clinical Course
Journal of Personalized Medicine,
Год журнала:
2025,
Номер
15(4), С. 156 - 156
Опубликована: Апрель 17, 2025
Background:
This
study
investigated
the
role
of
genetic
polymorphisms
in
IFNAR2,
OAS1,
OAS3,
and
ACE2
as
predictors
Paxlovid
treatment
response,
specifically
examining
their
influence
on
clinical
course
laboratory
parameters
COVID-19
patients.
Methods:
We
analyzed
impact
genes
associated
with
interferon
pathway
(IFNAR2
rs2236757),
antiviral
response
(OAS1
rs10774671,
OAS3
rs10735079),
viral
entry
(ACE2
rs2074192)
individuals
treated
Paxlovid.
Results:
Our
findings
suggest
that
variations
these
may
modulate
immune
coagulation
pathways
context
during
infection.
Specifically,
IFNAR2
rs2236757
G
allele
was
alterations
inflammatory
markers,
while
OAS1
influenced
parameters.
Furthermore,
specific
genotypes
were
linked
to
changes
such
oxygen
saturation,
leukocyte
count,
liver
function
markers
Paxlovid-treated
Conclusions:
These
results
highlight
potential
considering
factors
understanding
individual
responses
informing
future
personalized
approaches.
Язык: Английский
Changes in the incidence, clinical features and outcomes of tuberculosis during COVID-19 pandemic
Journal of Infection and Public Health,
Год журнала:
2024,
Номер
17(9), С. 102511 - 102511
Опубликована: Июль 26, 2024
COVID-19
pandemic
has
disrupted
tuberculosis
(TB)
services
in
many
countries,
but
the
impacts
on
sites
of
involvement,
drug
susceptibility,
smear
positivity
and
clinical
outcomes,
outcomes
co-infection
with
influenza
remain
unclear.
Язык: Английский
Potential associations of selected polymorphic genetic variants with COVID-19 disease susceptibility and severity
medRxiv (Cold Spring Harbor Laboratory),
Год журнала:
2024,
Номер
unknown
Опубликована: Март 14, 2024
Abstract
In
this
study,
we
analyzed
the
potential
associations
of
selected
laboratory
and
anamnestic
parameters,
as
well
12
genetic
polymorphisms
(SNPs),
with
clinical
COVID-19
occurrence
severity
in
869
hospitalized
patients.
The
SNPs
by
qPCR
were
based
on
population-wide
(GWAS)
data
previously
indicating
association
COVID-19.
We
confirmed
disease
several
parameters
found
an
unexpected
between
less
severe
loss
smell
taste.
most
cases,
SNP
analysis
supported
earlier
results
hospitalization
severity,
while
role
some
unrecognized
has
also
been
observed.
A
was
indicated
presence
a
reduced-function
ABCG2
transporter
variant
disease,
which
observed
diabetic
Our
current
results,
should
be
reinforced
larger
studies,
indicate
that
together
may
have
predictive
value
for
Язык: Английский